FRLN today announced the expansion of its executive leadership team with the appointment of James "Jay" Bircher as Chief Technical Operations Officer effective July 1, 2021.
Clinical-stage biotechnology company Freeline Therapeutics has announced a modification to the clinical development plan for its FLT180a programme for Hemophilia B.